The Clinical Evidence of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor, Dapaglifozin, a New Pillar of Treatment for Heart Failure with Reduced Ejection Fraction

Abstract

Heart failure with reduced ejection fraction (HFrEF) remains burdensome because its morbidity and mortality is still relatively high. The current treatments implementing multiple drugs for controlling symptoms and reduced fatal event have been proposed, however  the  mortality  rate  remains  constant.  Sodium-glucose  cotransporter-2 (SGLT2) inhibitor, a novel class of drugs, had been introduced as a new pillar for HFrEF treatment. The DAPA-HF trial showed the beneficial impression of dapagliflozin, an SGLT2  inhibitor,  on  reducing  the  risk  of  hospitalization  and  mortality  in  HFrEF patients with or without type 2 diabetes mellitus.